LABETALOL HYDROCHLORIDE by Teva is clinical pharmacology labetalol hydrochloride combines both selective, competitive, alpha 1 -adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. Approved for the management of hypertension. First approved in 1998.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Labetalol hydrochloride combines both selective, competitive, alpha 1 -adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 and 1:7…
Worked on LABETALOL HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.